Design of a prostate cancer patient navigation intervention for a Veterans Affairs hospital

Table 2 Patient characteristics, abnormal screen group (n = 490)

	All subjects (n = 490)
	*N (%)*
Age
< 65 years	261 (53%)
> = 65 years	229 (47%)
Mean	65.1
Median	63.5
Range	42-92
Race/ethnicity
African American	332 (68%)
White	105 (21%)
Other	27 (6%)
Not reported	26 (5%)
Screening eligibility
PSA test (> = 4.0 ng/mL)	414 (84%)
Abnormal PSA velocity	39 (8%)
Digital rectal exam	37 (8%)
Baseline PSA
< 4 ng/mL*	37 (8%)
4 ng/mL - 10 ng/mL	318 (65%)
> 10 ng/mL	98 (20%)
Not collected (Screen = DRE)	37 (8%)
Cancer diagnosis
No cancer or resolved with repeat PSA	244 (50%)
Cancer	170 (35%)
Unresolved	76 (16%)

Abbreviations: PSA, prostate specific antigen; ng/mL, Nanogram per milliliter; DRE, Digital rectal exam.
*Values may not sum to all subjects who enrolled on abnormal PSA velocity due to rounded PSA value.

ISSN: 1472-6963